设为首页 |  加入收藏
首页期刊介绍编委会投稿须知通知公告刊登文章继续教育园地协办单位联系我们广告合作
公告栏:
1例COVID-19危重型患者免疫治疗的疗效评估
作者:袁瑕1  王琳1  涂杰霞1  任雪松1  王静1  蒋正方2 
单位:1. 四川绵阳四0 四医院药学部, 四川 绵阳 621000;
2. 四川绵阳四0 四医院神经外科, 四川 绵阳 621000
关键词:新型冠状病毒肺炎 危重型 免疫治疗 胸腺法新 干扰素 免疫球蛋白 
中图分类号:R457.2;R967
文献标志码:
出版年,卷(期):页码:2021,31(1):53-56,
收稿日期:2020-5-13
摘要:
目的 探索COVID-19危重型患者免疫支持治疗的理论依据,以期为后续COVID-19危重型患者免疫相关治疗提供部分病例支持。方法 以我院收治的1例COVID-19危重型患者为对象,关注其免疫相关指标包括T淋巴细胞数量、CD4+T和CD8+T细胞计数的变化情况结合患者炎症指标白介素-6(IL-6)及临床症状的变化情况,进行相关性分析,评估免疫支持治疗的疗效及对患者预后的影响。结果 患者药物治疗过程与临床症状的变化情况有相关性,炎症指标IL-6、T淋巴细胞数量的变化情况与药物治疗方案的调整变化一致,提示免疫治疗有效。结论 增加T淋巴细胞数量的免疫支持治疗可能是COVID-19危重型患者的有效治疗方法之一。
OBJECTIVE To explore the theoretical basis of immune support therapy for critical patients with COVID-19, and to provide partial case support for subsequent immunological treatment for critical patients with COVID-19. METHODS A case of severe patient with COVID-19 was admitted to our hospital as a subject.The changes of immune-related indicators including the number of T lymphocytes, CD4+T and CD8+T cell counts combined with the patient's inflammation index interleukin-6(IL-6)and the change of clinical symptoms we paid attention.The correlation analysis was conducted to evaluate the efficacy of immune support therapy and its impact on the prognosis of patients. RESULTS The patient's drug treatment process was correlated with the changes in clinical symptoms.The changes in the inflammatory markers IL-6 and T lymphocytes were consistent with the adjustment changes in the drug treatment plan, which suggested that immunotherapy was effective. CONCLUSION Increasing the number of T lymphocytes in immunosupportive therapy may be one of the effective treatment methods for critical patients with COVID-19.
基金项目:
绵阳市新型冠状病毒感染肺炎疫情应急科研项目(2020YJKY013);四川省基层卫生事业发展研究中心项目(SWFZ19-Y-40)
作者简介:
袁瑕,主管药师,研究方向:临床药学
通讯作者:蒋正方,硕士生导师,主任医师,研究方向:脑血管外科基础与临床研究,E-mail:jiangfangzheng@sina.com
参考文献:
[1] 王辉强,马琳琳,蒋建东,等.重组人干扰素α2b体外广谱抗呼吸道病毒药效学研究[J].药学学报,2014,49(11):1547-1553.
[2] 李明慧,谢尧.慢性病毒性肝炎患者干扰素α治疗不良反应临床处理专家共识[J].临床肝胆病杂志,2014,30(11):1106-1111.
[3] 申昆玲,尚云晓,张国成,等.α干扰素在儿科临床合理应用专家共识[J].中华实用儿科临床杂志,2018,33(17):1301-1308.
[4] Seo Y J,Halm B.Type I interfemn modulates the battle of host immune system against vimses[J].Adv Appl Microbiol,2010,73:83-101. Doi:10.1016/S0065_2164(10)73004-5.
[5] 房晓伟,梅清,杨田军,等.2019新型冠状病毒感染的肺炎79例临床特征及治疗分析[J].中国药理学通报,2020,36(4):453-459.
[6] 庄方莉,刘永兴,黄晓展.静脉注射丙种球蛋白治疗新生儿感染效果评价[J].深圳中西医结合杂志,2019,29(23):168-169.
[7] 李太生,曹玮,翁利,等.北京协和医院关于"新型冠状病毒感染的肺炎"诊疗建议方案(V2.0)[J/OL].协和医学杂志:1-5[2020-03-02]. http://kns.cnki.net/kcms/detail/11.5882.r.20200130.1430.002.html.
[8] 赵东赤,金润铭,刘智胜,等.湖北省儿童新型冠状病毒感染诊疗建议(试行第一版)[J].中国当代儿科杂志,22(2):96-99.
[9] 李旭芳,郑健斌,徐翼,等.广东省儿科新型冠状病毒肺炎诊疗专家共识[J].广东医学,2020,41(3):217-221.
[10] Chen N, Zhou M, Dong X, et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China:a descriptive study[J]. Lancet,2020,395(10223):15-21.
[11] Wang D,Hu B,Hu C.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia Wuhan,China[J].JAMA,2020,323(11):1061-1069.
[12] Zhou W, Liu Y, Tian D D,et al.Potential benefits of precise corticosteroids therapy for severe 2019-nCoVpneumonia[J].Signal Transduct Target Ther, 2020, 5:18.
[13] 李玉明,王世鑫,高宏生,等.严重急性呼吸综合征患者康复期股骨头缺血性坏死和骨质疏松的影响因素[J].中华医学杂志,2004,84(16):1348-1353.
[14] Nelson L,Allen C K C,David S H, et al.Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients[J]. Journal of Clinical Virology,2005,31(4):304-309.
[15] Yaseen A,Yasser M,Fahad A, et al.Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome[J]. American Journal of Respiratory and Critical Care Medicine,2018,197(6):757-767.
[16] 袁静,骆子义,胡毅文,等.46例严重急性呼吸综合征患者的临床特征与药物治疗[J].医药导报,2003,22(12):832-834.
[17] 张益明,高世定,王占科,等.3例新型冠状病毒肺炎患者外周血CD4+T淋巴细胞和CD4+/CD8+比值变化[J].国际检验医学杂志,2020,41(17):2173-2176.
[18] 艾香英,谢敏,林路平,等.广州29例境外输入型新型冠状病毒肺炎的临床特点分析[J].今日药学,2020,30(7):442-445,452.
服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
 
友情链接  
广东今日药学杂志社有限公司   地址:广州市东风东路753号东塔7楼702
电话:020-37886325       邮箱:jinriyaoxue@163.com
本系统由北京博思汇文数字科技有限公司设计开发 技术服务电话:400-921-9838
粤ICP备20054928号

粤公网安备 44010402002138号

您是第 187158 位访问者